![](https://www.diabetesnews.com/wp-content/uploads/2012/05/No_Dead_Space_Insulin_Syringes_28g_29g-150x150.jpg)
In 2 phase 3 trials examining the concept of triweekly dosing with the long-acting insulin degludec (Tresiba, Novo Nordisk) in patients with type 2 diabetes, the recipients had inferior glucose control and an increased risk for hypoglycemia.
Read more